№ files_lp_3_process_7_085013
File format: docx
Character count: 42563
File size: 87 KB
Year:
2021
Region / City:
Australia
Topic:
Neuropathic pain, Pregabalin CR, Pharmaceutical Submission
Document Type:
Submission for Pharmaceutical Listing
Organization:
Upjohn Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical Practitioners, Pharmaceutical Regulators
Action Period:
Not specified
Approval Date:
10 March 2021
Modification Date:
Not specified
Clinical Criteria:
Condition must be refractory to other treatments
PBS Indication:
Neuropathic pain in adults
Treatment Phase:
Initial and continuing
Prescriber:
Medical Practitioners, Nurse Practitioners for continuing therapy
Source:
Therapeutic Goods Administration (TGA)
Background:
Pregabalin CR tablets were registered in Australia in March 2021 for neuropathic pain in adults.
Purpose of Submission:
Request for listing pregabalin CR on the PBS for neuropathic pain treatment under the same clinical criteria as pregabalin IR
International Registration Status:
Approved in the USA (2017) and Republic of Korea (2018) for neuropathic pain treatment
Requested Listing:
Pregabalin CR tablets for inclusion in PBS under a General Schedule (GE)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Language:
English
Medical field:
Pain management
Therapeutic class:
Gabapentinoids
Medications covered:
Gabapentin; Pregabalin
Indications discussed:
Neuropathic pain
Patient population:
Adults with persistent pain
Document type:
Clinical guidance
Related guidance:
Analgesic Tapering Guidelines for adult patients with persistent pain taking strong opioids and/or gabapentinoids
Regulatory references:
NICE; MHRA
Dosage information:
Included
Tapering schedules:
Included
Risk considerations:
Adverse effects; withdrawal effects; opioid co-prescribing risks
Geographic context:
United Kingdom
Evidence sources:
Cochrane Reviews; NICE guidance; Summary of Product Characteristics
Year:
2026
Region / City:
Missouri, USA
Topic:
Neuropathic Pain Agents
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers and MO HealthNet participants
Approval Period:
1 year
Approval Date:
January 20, 2026
Revision Date:
May 29, 2013
Year:
2012
Location:
Port St. Lucie, Florida, USA
Topic:
Chronic and Neuropathic Pain Management
Document Type:
Event Invitation
Organization:
Treasure Coast Nurse Practitioner Association
Sponsor:
Depomed
Representative:
Laurel Briggs
Guest Speaker:
Bruce Hendi, R.Ph, DO
Target Audience:
Nurse Practitioners
Event Date:
September 1, 2012
Event Time:
6:30 PM
Venue:
Tutto Fresco, 905 Reserve Blvd
Registration:
Required via ENP Network website
Year:
2023
Region / City:
Global
Theme:
Faith, Spiritual Growth, Biblical Teachings
Document Type:
Sermon, Bible Study
Organization:
Christian Ministry
Author:
Unspecified
Target Audience:
Christians, those seeking spiritual guidance
Period of Validity:
N/A
Date of Approval:
N/A
Date of Changes:
N/A
Year:
2021
Region / city:
East and North Hertfordshire
Topic:
Pain Management
Document Type:
Patient Information Leaflet
Institution:
East and North Hertfordshire NHS Trust
Author:
Not specified
Target Audience:
Patients seeking pain management follow-up
Period of validity:
9 months
Approval Date:
2021/12/15
Review Date:
2025/01/01
Publication Date:
2021/12/15
Contact Information:
01438 288616
Office Hours:
Monday to Friday, 9am to 4pm
Circumstances for Appointment:
Change in treatment, side effects, pregnancy planning
End of Service:
9 months from initiation of PIFU
Description:
A patient information leaflet detailing the process and conditions for patient-initiated follow-up (PIFU) regarding pain management services.
Note:
Year
Theme:
Pain management
Document type:
Self-assessment tool
Target audience:
Healthcare providers, facility staff
Context:
Tool for examining and improving pain management practices in healthcare facilities through self-assessment.
Year:
2023
Region / city:
Canberra
Subject:
Chronic Kidney Disease, Pain Management
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Unknown
Target Audience:
CHS medical staff
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / city:
Not specified
Topic:
Long-Term Opioid Therapy
Document type:
Informed Consent Form
Organization / institution:
VA (Veterans Affairs)
Author:
Not specified
Target audience:
Patients receiving opioid therapy for chronic pain
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Context:
Informed consent document outlining the risks, benefits, and conditions of long-term opioid therapy for chronic pain management.
Year:
2026
Region / City:
Gothenburg, Sweden
Topic:
6G, UE Capability, RAN2
Document Type:
Meeting Report
Organization:
3GPP TSG RAN WG2
Author:
Xiaomi
Target Audience:
Companies and organizations involved in 3GPP standards
Period of Effect:
2025-2026
Approval Date:
February 9th, 2026
Modification Date:
January 23rd, 2026
Year:
2026
Region / City:
Missouri, USA
Topic:
Neuropathic Pain Agents
Document Type:
Proposal
Institution:
MO HealthNet
Author:
MO HealthNet and Conduent
Target Audience:
Healthcare providers and MO HealthNet participants
Approval Period:
1 year
Approval Date:
January 20, 2026
Revision Date:
May 29, 2013
Year:
2026-2029
Region / City:
Scotland
Topic:
Chronic Pain Management
Document Type:
Guidance
Organization:
Scottish Government
Target Audience:
Healthcare professionals, individuals experiencing chronic pain
Implementation Period:
2026-2029
Approval Date:
Not specified
Amendment Date:
Not specified
Context:
A consultation document from the Scottish Government aimed at gathering feedback on recommendations for the management of chronic pain, including medication review, communication, non-pharmacological approaches, and opioid stewardship.
Year:
2026
Region / City:
Not specified
Subject:
Chronic pain management
Document type:
Clinical guidance / Flowchart
Institution:
Healthcare provider / Multidisciplinary team
Target audience:
General practitioners, advanced nurse practitioners, physiotherapists, occupational therapists, pharmacists
Key concepts:
Pain assessment, differential diagnosis, rehabilitation, medication management, referral criteria
Clinical setting:
Outpatient / Primary care
Patient considerations:
Functional deficits, distress, polypharmacy, suspected drug-seeking behaviour
Interventions:
Education, self-management, physiotherapy, occupational therapy, pharmacological review, pain team referral
Year:
2020
Region / City:
New Zealand
Topic:
Pain management, medical referral
Document type:
Form
Author:
ACC
Target Audience:
Healthcare professionals, ACC claimants
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Language:
English
Medical field:
Pain management
Therapeutic class:
Gabapentinoids
Medications covered:
Gabapentin; Pregabalin
Indications discussed:
Neuropathic pain
Patient population:
Adults with persistent pain
Document type:
Clinical guidance
Related guidance:
Analgesic Tapering Guidelines for adult patients with persistent pain taking strong opioids and/or gabapentinoids
Regulatory references:
NICE; MHRA
Dosage information:
Included
Tapering schedules:
Included
Risk considerations:
Adverse effects; withdrawal effects; opioid co-prescribing risks
Geographic context:
United Kingdom
Evidence sources:
Cochrane Reviews; NICE guidance; Summary of Product Characteristics
Year:
2019
Organization:
The Royal Australian College of General Practitioners (RACGP)
Document type:
Policy template
Purpose:
Safe limitations for prescribing opioid medication
Scope:
Non-malignant pain
Current as of:
[insert date of last revision]
Version no:
[insert version number]
Review date:
[insert date]
Target audience:
General practitioners
Source:
RACGP Clinical Governance Framework
Year:
2018
Region / City:
Scotland
Topic:
Chronic pain management, gabapentinoids prescribing
Document type:
Guideline
Organization / Institution:
Scottish Government
Author:
Heather Harrison, Jason Cormack
Target audience:
Clinicians, healthcare professionals, Boards
Period of validity:
Ongoing
Approval date:
11th December 2018
Date of revisions:
Not specified